The bioT3 Metastatic Cancer Solution, a rebranded suite of cancer assays from bioTheranostics, San Diego, offers a series of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care. The CancerType ID molecular classifier enables diagnosis of tumor type and subtype and is supported by clinical evidence confirming its diagnostic accuracy, clinical utility, and impact on patient outcomes. CancerTarget ID, previously marketed as Precis Precision Medicine, offers tumor-specific biomarker profiles for selection of on-label targeted therapies. CancerTreatment ID, the newest product, combines next-generation sequencing and multi-platform predictive biomarkers to analyze 50 cancer-related genes for mutations that may be driving tumor growth. For more information, visit bioTheranostics.
LabCorp Offers Ovarian-Cancer Test For High-Risk Women
June 26, 2008
Predictive Biosciences: Clinical Study of Bladder Cancer Assay
October 22, 2012
New Saliva Test Detects Head and Neck Cancer
June 10, 2021